Krystal Biotech shares are trading higher after the company sold its Rare Pediatric Disease Priority Review Voucher for $100M.
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech has sold its Rare Pediatric Disease Priority Review Voucher for $100M, leading to a rise in its share prices.
August 21, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's stock price is rising after the company sold its Rare Pediatric Disease Priority Review Voucher for $100M.
The sale of the Rare Pediatric Disease Priority Review Voucher for $100M has brought in significant revenue for Krystal Biotech, which is a positive development for the company. This has led to increased investor confidence, resulting in a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100